about
Cutaneous Leishmaniasis Vaccination: A Matter of QualityIron overload favors the elimination of Leishmania infantum from mouse tissues through interaction with reactive oxygen and nitrogen speciesImmunoadjuvant Properties of the Rho Activating Factor CNF1 in Prophylactic and Curative Vaccination against Leishmania infantumEnhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigenVaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice modelsEvaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasisA novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts.Evaluation of Alum-Naltrexone Adjuvant Activity, on Efficacy of Anti-Leishmania Immunization with Autoclaved Leishmania major (MRHO/IR/75/ER) Antigens in BALB/C Mice.An overview on Leishmania vaccines: A narrative review article.One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasisEffect of trinitroglycerin therapy on serum zinc and copper levels and liver enzyme activities in BALB/c mice infected with Leishmania major MRHO/IR/75/ER.The economic value of a visceral leishmaniasis vaccine in Bihar state, India.Host-parasite interaction: parasite-derived and -induced proteases that degrade human extracellular matrix.Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania major (Alum-ALM) Vaccine Mixed With BCG Plus Imiquimod Vs. Placebo Control Group.The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in miceMitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine.Clinical and Immunological Analysis of Cutaneous Leishmaniasis before and after Different Treatments.A Novel Spirooxindole Derivative Inhibits the Growth of Leishmania donovani Parasites both In Vitro and In Vivo by Targeting Type IB TopoisomeraseLeishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.Therapeutic vaccines for leishmaniasis.Particle induced X-ray emission study of blood samples of Indian Kala-azar patients.Evaluation of the alum-naloxone adjuvant activity against experimental murine leishmaniasis due to L. major.Leishmania donovani-specific 25- and 28-kDa urinary proteins activate macrophage effector functions, lymphocyte proliferation and Th1 cytokines production.3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.Plasmid pVAX1-NH36 purification by membrane and bead perfusion chromatography.Segregated growth kinetics of Escherichia coli DH5α-NH36 in exponential-fed perfusion culture for pDNA vaccine production.Variability of Cutaneous Leishmaniasis Lesions Is Not Associated with Genetic Diversity of Leishmania tropica in Khyber Pakhtunkhwa Province of Pakistan.Cloning and Expression of Leishmania infantum LPG3 Gene by the Lizard Leishmania Expression System.An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.Multi-analytical platform metabolomic approach to study miltefosine mechanism of action and resistance in Leishmania.Immunization against full-length protein and peptides from the Lutzomyia longipalpis sand fly salivary component maxadilan protects against Leishmania major infection in a murine model.Synthesis and Leishmanicidal Activity of 1-[5-(5-Nitrofuran-2-yl)-1, 3, 4-Thiadiazole-2-yl]-4-BenzoylePiperazines.To investigate the therapeutic potential of immunochemotherapy with cisplatin + 78 kDa + MPL-A against Leishmania donovani in BALB/c mice.Centrin-Deleted Leishmania donovani Parasites Help CD4+ T Cells to Acquire Th1 Phenotype and Multi-Functionality Through Downregulation of CD200-CD200R Immune Inhibitory Axis.
P2860
Q26752521-38E64C39-0E65-4746-8A8B-CD178D39BA4CQ27305261-0054F4C8-41D0-4ABD-9500-04EDD7E42E3AQ27342880-2BA202AF-BDC6-4B19-85EC-0BA75567B2F3Q28541600-0358C856-9835-4F15-B55C-A81C636D0F68Q33783745-85156A44-79EF-4A3A-BF87-B4D66F5E4F63Q34515998-39F7097E-0298-4E48-A133-E3A00A9AE891Q34669706-89F251E0-0974-4065-B4CD-3492738534C1Q35047309-740185AF-F373-4EC1-A780-DE8C6970B8DAQ35517074-162BBB4C-4CE9-44BA-B371-63ED9C460B64Q35518943-3D72731B-45EF-42B0-B4E3-6D74DA5AA36EQ35555029-62419CE6-8CA1-441C-96F2-4E49CDFB48B5Q35771782-16623BD8-0AE7-4B84-A00A-0BE12A2A7CF2Q36077428-AC2096BD-E088-4025-BD55-1C5C719DF9BBQ36327194-60DF63F2-9073-4574-B0C2-9A8F7FFACFD1Q36379560-C6E7B631-E198-4894-B6C4-E2F87D68FF78Q36415941-F29E7D8F-6348-43CC-9CF3-F33FA8554565Q36970088-30E825C3-7BA2-4770-B50B-D30F1EB32FC6Q37287656-332E406B-42D0-4A06-9EC5-FDCDF798DC49Q37965724-BAA52104-B814-454A-8A19-D0B625026F34Q38235456-8155EBD7-A5DF-417B-8CFB-94C8BA442355Q38895807-F08FD81A-3167-4599-A5FE-9D8B14B33D05Q39017213-C2DBBB19-5DFF-4006-B5E0-432378747EFDQ39207671-11C5633E-FFBE-40F6-AF71-D3129439BB49Q39575305-46D9B60E-C9DC-4623-8A28-CC541A39CC2FQ40425661-5D677186-8EBC-4ECF-9990-15CF8943338FQ41628326-EA7BADBB-04F7-4AA1-BC2E-CC0A30158A3CQ41989168-49F74576-9887-488B-A017-E5F147497C75Q43061770-E1A9F3E0-B6C1-4E00-811D-FCD1DF368B20Q46275091-BF622F97-3471-4167-BDC0-EA796D2F33DAQ46907074-4CDD4356-A63E-420D-AB12-AE4DAA5346E6Q47094812-28489728-9048-4AC4-866C-DF19FE76A21DQ47103950-DA353CC9-8921-4FDA-866B-4EDA4EE66691Q47732162-48FF9B75-65C8-45D2-AE55-7C0817E61EC8Q55262888-3BE8A322-F990-418C-B0D9-524D0383ECD5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vaccine candidates for leishmaniasis: a review.
@en
Vaccine candidates for leishmaniasis: a review.
@nl
type
label
Vaccine candidates for leishmaniasis: a review.
@en
Vaccine candidates for leishmaniasis: a review.
@nl
prefLabel
Vaccine candidates for leishmaniasis: a review.
@en
Vaccine candidates for leishmaniasis: a review.
@nl
P1476
Vaccine candidates for leishmaniasis: a review.
@en
P2093
Rajeev Nagill
Sukhbir Kaur
P304
P356
10.1016/J.INTIMP.2011.05.008
P577
2011-05-25T00:00:00Z